1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Warren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli Lilly to dividend-paying stalwarts like Johnson & Johnson and Abbott Laboratories that provide steady earnings and income.

06/03/2026, 12:05 PM • The Motley Fool

S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today

U.S. equities hit fresh record highs on May 6, 2026, with the S&P 500 and Nasdaq 100 reaching all-time peaks. AMD and Super Micro Computer surged 16% on strong AI-driven earnings, while oil prices collapsed 6-7% on diplomatic hopes between Washington and Tehran. Technology stocks led gains, though energy stocks declined sharply. Mixed earnings results saw winners like Flex Ltd. (+30%) and DaVita (+18%), while CDW and Coupang fell 20% and 17.5% respectively.

05/06/2026, 1:35 PM • Benzinga

Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health

The American Heart Association has introduced the Cardiovascular-Kidney-Metabolic (CKM) Health Initiative to increase awareness of the interconnected nature of heart disease, kidney disease, diabetes, and obesity. Nearly 90% of U.S. adults have at least one CKM risk factor, yet many cases remain undiagnosed. The initiative encourages regular screening and lifestyle modifications to prevent complications.

03/30/2026, 1:33 PM • GlobeNewswire

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

R1 Therapeutics, a new clinical-stage biopharmaceutical company, launched with an oversubscribed $77.5 million Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime. The company licensed exclusive global rights (outside Greater China) to AP306 from Alebund Pharmaceuticals, a first-in-class pan phosphate transporter inhibitor for treating hyperphosphatemia in chronic kidney disease patients on dialysis. R1 plans to advance Phase 2b clinical development of AP306, addressing a significant unmet need affecting over 40% of US dialysis patients.

03/17/2026, 7:00 AM • GlobeNewswire

3 No-Brainer Warren Buffett Stocks to Buy Right Now

Following Warren Buffett's retirement and Greg Abel's appointment as CEO of Berkshire Hathaway, the article highlights three Warren Buffett stocks with solid long-term potential: Chevron, benefiting from rising oil prices and operational improvements; Domino's Pizza, outperforming competitors with positive same-store sales growth and potential for higher valuation; and DaVita, showing signs of quiet recovery with strong Q4 results and promising 2026 guidance despite past struggles.

03/13/2026, 11:15 PM • The Motley Fool

2 Warren Buffett Stocks to Buy Hand Over Fist This Month, and 1 to Avoid

The article analyzes three Warren Buffett holdings: American Express is recommended as a buy despite a 20% pullback due to its strong position with affluent borrowers; Constellation Brands is suggested as a buying opportunity despite current weakness, as the beer industry is cyclical and the company is undergoing strategic improvements; DaVita is flagged as a stock to avoid due to deteriorating healthcare industry fundamentals and Berkshire's recent exit from the position.

03/08/2026, 4:25 AM • The Motley Fool

How Berkshire Hathaway Performed During Buffett’s Final Quarter

Warren Buffett stepped down as Berkshire Hathaway CEO on December 31, 2025, after 60+ years. Q4 2025 results showed mixed performance with lower earnings due to $4.5B in impairments, but the company maintained a near-record $373.3B cash reserve. Buffett's final quarter moves included increasing positions in Chubb, Chevron, and The New York Times, while reducing stakes in Amazon, Bank of America, and DaVita. Over his tenure, Berkshire achieved 19.7% average annual gains versus the S&P 500's 10.2%.

03/04/2026, 7:29 AM • Investing

How Berkshire Hathaway Performed During Buffett’s Final Quarter

Warren Buffett stepped down as Berkshire Hathaway CEO on December 31, 2025, after 60+ years. Q4 2025 results showed mixed performance with lower earnings due to $4.5B in impairments, but the company maintained a near-record $373.3B cash reserve. Buffett's final quarter moves included increasing positions in Chubb, Chevron, and The New York Times, while reducing stakes in Amazon, Bank of America, and DaVita. Over his tenure, Berkshire achieved 19.7% average annual gains versus the S&P 500's 10.1%.

03/04/2026, 6:24 AM • Investing

2 Warren Buffett Stocks to Buy Hand Over Fist in 2026 and 1 to Avoid

The article analyzes three Berkshire Hathaway holdings: DaVita and Kraft Heinz are recommended as strong buys due to positive earnings surprises and undervaluation, while UnitedHealth Group should be avoided despite recent dips, as it trades at a premium valuation with a deteriorating growth story amid lower Medicare Advantage payment increases.

02/08/2026, 10:30 PM • The Motley Fool

Warren Buffett's Successor Greg Abel Just Sold This Long-Time Berkshire Hathaway Holding

Greg Abel, the new CEO of Berkshire Hathaway, has made his first reported stock sale by divesting 1.7 million shares of DaVita under a contractual agreement. The article also highlights Kraft Heinz as a potential candidate for sale, as Abel has registered to sell nearly all of Berkshire's 325 million shares and expressed disapproval of the company's planned split into two entities.

02/06/2026, 5:30 AM • The Motley Fool

DaVita Stock Rallies On Profit Beat, Confident 2026 View

DaVita Inc. (NYSE: DVA) surged 21.69% after reporting Q4 adjusted earnings of $3.40 per share, beating consensus of $3.16, and sales of $3.62 billion, up 5.8% YoY. The kidney care provider issued optimistic 2026 guidance with adjusted earnings of $13.60-$15.00 per share versus consensus of $12.65. The company also announced a $200 million minority investment in Elara Caring alongside Ares' Private Equity Group.

02/03/2026, 12:25 PM • Benzinga

What Sent DaVita Stock Soaring On Tuesday?

DaVita stock surged 20.3% on Tuesday following better-than-expected Q4 2024 earnings and improved full-year 2025 guidance. The dialysis treatment company reported adjusted EPS of $3.40 versus $2.51 year-over-year and projects 2025 EPS between $13.60-$15.00, significantly above the $10.78 achieved in 2024. Despite ongoing challenges from insurance reimbursement pressures and competition from home-based dialysis options, the stock appears undervalued at approximately 10x forward earnings.

02/03/2026, 12:18 PM • The Motley Fool

The Heart-Body Connection: How Other Organ Systems Affect Heart Health

A new American Heart Association initiative highlights the interconnected health of heart, kidney, and metabolic systems, revealing that 9 in 10 U.S. adults have at least one component of CKM syndrome, which increases risks of heart attack, stroke, and heart failure.

11/03/2025, 2:35 PM • GlobeNewswire

3 Warren Buffett Stocks to Buy Hand Over Fist in November

Warren Buffett's Berkshire Hathaway recommends three stocks currently out of favor: DaVita, Kraft Heinz, and Pool Corporation. Each stock offers unique investment potential despite current market challenges.

11/02/2025, 1:07 PM • The Motley Fool

3 Healthcare Stocks That Are Screaming Deals Right Now

The article highlights three healthcare stocks trading at attractive valuations: DaVita, Merck, and Universal Health Services, which offer potential investment opportunities despite current market challenges.

10/26/2025, 4:23 PM • The Motley Fool